Opioid Addiction Trial Gets Underway


The long-anticipated trial of 4 drugmakers in California has begun; a decide could quickly point out how a lot it should value the 4 firms concerned to resolve their legal responsibility for the opioid disaster.

The Wall Street Journal:
Drugmakers Accused Of Causing Opioid Addiction In Trial 

A lawyer for a number of giant California communities accused 4 drugmakers of inflicting a lethal wave of opioid dependancy with their aggressive advertising of ache drugs, whereas protection attorneys stated the corporations adopted the regulation, on the opening day of a trial intently watched by the pharmaceutical trade. “With out an avalanche of prescription opioids, there wouldn’t be an opioid epidemic,” stated Fidelma Fitzpatrick, a plaintiffs’ lawyer employed to signify the counties of Los Angeles, Orange and Santa Clara and the town of Oakland. (Randazzo, 4/19)

J&J, Teva Opioid Trial May Signal Cost of Drug Maker Accords

A California decide could quickly present a clearer image of what it should value drug makers together with Johnson & Johnson and Teva Pharmaceutical Industries Ltd. to resolve legal responsibility for his or her position within the U.S. opioid epidemic. The primary trial towards opioid firms in virtually two years began Monday in Santa Ana, the place 4 California municipalities are demanding at the least $50 billion for what they declare was the unlawful advertising of ache drugs. The case, which shall be determined with out a jury and tried just about, could also be a street map for hundreds of comparable claims pending towards drug makers, distributors and pharmacies. (Feeley, 4/19)

A New Book Traces The Roots Of The Opioid Crisis Through The Sackler Family

The household behind the OxyContin maker Purdue Pharma was already below intense authorized and public scrutiny after they discovered in 2019 that comic John Oliver was planning on doing a phase about them on his present, “Final Week Tonight.” However being the goal of a social commentary like Oliver’s struck a chord for at the least one member of the Sackler household. (Joseph, 4/20)

In different pharmaceutical trade information —

A PBM Offered A $500 Gift Card To Persuade Patients To Switch Drugs

Dozens of affected person advocacy teams are offended over an uncommon transfer by a well being insurer that lately started providing $500 debit playing cards to individuals who agree to change psoriasis medicines after it eliminated a extensively used drug from a number of of its formularies. At challenge is a choice by Cigna (CI) to supply the debit playing cards as an incentive to psoriasis sufferers to attempt options to a Novartis (NVS) remedy known as Cosenytx. (Silverman, 4/19)

North Carolina Health News:
Behind Needle Exchange Bill, A Spat Between Asheville Site And Its New Neighbors 

Proposed state laws filed in response to a years-long feud between an Asheville neighborhood and a neighborhood needle alternate might threaten syringe exchanges throughout North Carolina. Senate Invoice 607 seeks to ban cellular exchanges, require engraved needles, background checks, pressured remedy and extra. In the meantime, opioid overdose deaths are at an all-time excessive. (Knopf, 4/20)

Parexel’s Owner Is Said To Weigh Sale Of Drug-Trial Company

The proprietor of Parexel Worldwide Corp., which helps drugmakers run medical trials, is working with an adviser on a possible sale that would worth the corporate at a number of billion {dollars}, based on folks conversant in the matter. Non-public fairness agency Pamplona Capital Administration can be contemplating taking Parexel public, stated one of many folks, who requested to not be recognized as a result of the matter isn’t public. It has drawn takeover curiosity from personal fairness corporations and different firms, the folks stated. (Davis, Baigorri and Porter, 4/19)

That is a part of the KHN Morning Briefing, a abstract of well being coverage protection from main information organizations. Join an email subscription.


Source link

Related posts

Leave a Comment